STAAR Surgical Company Reports Strong Sales Despite Challenges in China Market

STAAR Surgical Company Reports Robust Sales Amid Challenges in China

STAAR Surgical Company, renowned for its innovative EVO family of Implantable Collamer® Lenses (EVO ICL™), reveals its fourth quarter and full fiscal year results for 2024, showcasing a resilient performance despite facing significant hurdles in the Chinese market. In Q4 2024, STAAR achieves net sales of $49.0 million, with a remarkable $46.9 million stemming from ICL sales. Notably, the company's performance in China accounts for $7.5 million of this figure, underscoring both the potential and the obstacles within this crucial market. Excluding China, ICL sales witness a substantial 17% year-over-year increase, reaching $39.5 million, reflecting strong demand for STAAR's advanced lens technology globally.

For the entire fiscal year, STAAR's net sales soar to $313.9 million, predominantly driven by ICL sales amounting to $312.5 million, which includes an impressive $161.0 million generated from China. This data highlights the critical role China plays in the company's overall revenue generation. However, STAAR experiences a net loss of $20.2 million, a stark contrast to the net income of $21.3 million reported in the previous year. The shift results in a net loss per share of $(0.41) compared to earnings per share of $0.43 in the prior fiscal year. The adjusted EBITDA decreases significantly to $23.2 million from $56.8 million the year before, indicating challenges in maintaining profitability amidst fluctuating market conditions.

Despite these setbacks, CEO Tom Frinzi expresses optimism about the company's future. He notes that while the demand in China has negatively impacted overall performance, STAAR anticipates double-digit growth in other international markets in 2025. The enduring demand for ICL technology positions STAAR favorably as it navigates current challenges. With cash and investments totaling $230.5 million, STAAR is well-equipped to continue investing in growth strategies, further solidifying its leadership in the refractive market. The company’s commitment to innovation and market expansion, particularly outside of China, underlines a strategic focus that may enable a rebound in the coming fiscal period.

In summary, STAAR Surgical’s latest results reflect both the strengths and challenges of its business. While the company faces difficulties in the Chinese market, its strong sales figures and cash reserves position it to pursue growth opportunities globally. The leadership remains confident in STAAR’s ability to recover and thrive, leveraging its cutting-edge ICL technology to meet the evolving needs of the refractive surgery market.